Myriad Genetics, Inc. revenue by segment MYGN

Annual Quarterly

Myriad Genetics, Inc. splits its revenue into 17 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Hereditary Cancer at $372.4 million, 45% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2026 Jun 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Jun 30, 2020	FY 2019 Jun 30, 2019	FY 2018 Jun 30, 2018	FY 2017 Jun 30, 2017	FY 2016 Jun 30, 2016
Revenue	807	824	838	753	678	691	639	851	744	771	754
Testing Revenue	—	—	—	—	678 +1.8% share 100.0%	666 share 96.5%	—	—	—	—	—
Hereditary Cancer	—	372 +2.2% share 45.2%	364 +11.2% share 43.5%	328 +7.3% share 43.5%	306 share 45.0%	—	—	—	—	—	—
Hereditary Cancer Testing	—	—	—	—	—	316 -9.0% share 45.8%	347 -27.6% share 54.4%	480 +1.8% share 56.4%	471 -10.3% share 63.4%	526 share 68.1%	—
Prenatal	—	186 +5.2% share 22.6%	177 +17.1% share 21.1%	151 share 20.1%	—	—	—	—	—	—	—
Prenatal Health	—	—	—	151 +30.0% share 20.1%	116 share 17.2%	—	—	—	—	—	—
Mental Health	—	144 -15.3% share 17.5%	170 +22.9% share 20.3%	138 +8.5% share 18.4%	128 share 18.8%	—	—	—	—	—	—
Tumor Profiling	—	122 -3.3% share 14.8%	126 -7.2% share 15.0%	136 share 18.0%	—	—	48 +12.3% share 7.6%	43 share 5.1%	—	—	—
Molecular Diagnostic Pharmacogenomics	—	—	—	—	—	—	—	113 share 13.2%	—	78 share 10.2%	—
Prenatal Testing	—	—	—	—	—	107 +39.2% share 15.5%	77 share 12.0%	—	—	—	—
Pharmacogenomics	—	—	—	—	—	94 +26.5% share 13.6%	74 share 11.6%	—	—	—	—
Molecular Diagnostic Autoimmune	—	—	—	—	—	—	—	48 -12.5% share 5.7%	55 +22.1% share 7.4%	45 share 5.9%	—
Molecular Diagnostic Prolaris Testing	—	—	—	—	—	—	—	26 +18.6% share 3.0%	22 +93.7% share 2.9%	11 share 1.4%	—
Pharmaceutical And Clinical Services	—	—	—	—	—	24 -53.2% share 3.5%	52 -16.2% share 8.1%	62 +15.8% share 7.2%	53 +8.1% share 7.2%	49 share 6.4%	—
Molecular Diagnostic Endo Predict Testing	—	—	—	—	—	—	—	10 +18.2% share 1.2%	9 +14.3% share 1.2%	8 share 1.0%	—
Other Testing	—	—	—	—	—	0 share 0.1%	—	—	—	—	—
Molecular Diagnostic Other Testing	—	—	—	—	—	0 -61.5% share 0.1%	1 +44.4% share 0.2%	1 -89.5% share 0.1%	9 -25.2% share 1.2%	12 share 1.5%	—
Autoimmune	—	—	—	—	0 -98.9% share 0.0%	28 -27.9% share 4.1%	39 share 6.1%	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: In Vitro & In Vivo Diagnostic Substances (SIC 2835)
Listed as: MYGN (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Salt Lake City, UT
SEC filer status: Accelerated filer
SEC CIK: 899923
Former names: MYRIAD GENETICS INC (until Nov 5, 2026)

Other In Vitro & In Vivo Diagnostic Substances companies

All 21 In Vitro & In Vivo Diagnostic Substances companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.